Comparing two hepatitis B treatments in young children
Treatments studied
Part of Digestive system, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study tests whether adding a second medicine to the standard hepatitis B treatment helps young children clear the virus better. It may help improve liver health and reduce long-term risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 3 and 6 years old
- Child has chronic hepatitis B with a positive HBeAg test
- Child's viral load is high (above 10,000 IU/mL)
- Child has elevated liver enzyme (ALT) levels above the normal range
- Child has not been treated for hepatitis B before
- Child does not have other liver diseases or serious health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
This study looks at how well antiviral medicines work in children with chronic hepatitis B. It may help doctors find better ways to treat children who are starting treatment or who have been on treatment for a while.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
This study tests a combination of two medicines for chronic hepatitis B: pegylated interferon and a nucleoside analogue. The goal is to see if this combo helps clear the hepatitis B surface antigen and improves the chance of a functional cure.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.